Population-based meta-Analysis of furosemide pharmacokinetics

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 2, 2014, Pages 119-133

  Van Wart, Scott A ^a,b   Shoaf, Susan E ^c   Mallikaarjun, Suresh ^c   Mager, Donald E ^b  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

cirrhosis; furosemide; heart failure; population pharmacokinetics

Indexed keywords

FUROSEMIDE; TOLVAPTAN; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DIURETIC THERAPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; EDEMA; FEMALE; HUMAN; HYPERTENSION; HYPERVOLEMIA; KIDNEY FUNCTION; LIVER CIRRHOSIS; MALE; NORMAL HUMAN; POPULATION RESEARCH; PREDICTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; URINARY EXCRETION; BIOLOGICAL MODEL; BLOOD; HEART FAILURE; META ANALYSIS; MIDDLE AGED; URINE; YOUNG ADULT;

ADULT; DIURETICS; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; YOUNG ADULT;

EID: 84896713620     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1874     Document Type: Article

References (63)

1. Burg MB,. Tubular chloride transport and the mode of action of some diuretics. Kidney Int 1976; 9: 189-197.
2. Odlind B, Beermann B,. Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 1980; 27: 784-790. (Pubitemid 10072965)
3. Kaojarern S, Day B, Brater DC,. The time course of delivery of furosemide into urine: an independent estimate of overall response. Kidney Int 1982; 22: 69-74. (Pubitemid 12091220)
4. Wakelcamp M, Alvan G, Paintaud G,. Natriuretic efficiency of frusemide as a consequence of drug input rate. Br J Clin Pharmacol 1997; 43: 481-491. (Pubitemid 27224008)
5. Hunt SA, Abraham WT, Chin MH, et al,. American College of Cardiology/American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2009; 53: 1-90. doi: 10.1016/j.jacc.2008.11.013.
6. Clear NJ, Milton A, Humphrey M, et al,. Evaluation of the intelisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon. Eur J Pharm Sci 2001; 13: 375-384. (Pubitemid 32618646)
7. Granero GE, Longhi MR, Mora MJ, et al,. Biowaver monographs for immediate release solid oral dosage forms: furosemide. J Pharm Sci 2010; 99 (6): 2544-2556. doi: 10.1002/jps.22030.
8. Waller ES, Hamilton SF, Massarella JW, et al,. Disposition and absolute bioavailability of furosemide in healthy males. J Pharm Sci 1982; 71: 1105-1108. (Pubitemid 12032671)
9. Grahnen A, Hammarlund M, Lundqvist T,. Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol 1984; 27: 595-602. (Pubitemid 15176768)
10. Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, Benet LZ,. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-Associated proteins (MRP1 and MRP2). Pharmacology 2002; 64: 126-134. (Pubitemid 34136853)
11. Cutler RE, Forrey AW, Christopher TG, Kimpel BM,. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin Pharmacol Ther 1974; 15: 588-596.
12. Beermann B, Dalén E, Lindström B, Rosén A,. On the fate of furosemide in man. Eur J Clin Pharmacol 1975; 9: 51-61.
13. Ponto LL, Schoenwald RD,. Furosemide (frusemide). A pharmacokinetic- pharmacodynamic review (Part I). Clin Pharmacokinet 1990; 18: 381-408. (Pubitemid 20134544)
14. Shoaf SE, Bramer SL, Bricmont P, Zimmer CA,. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 2007; 50 (2): 213-222. (Pubitemid 47267748)
15. Brater DC, Chennavasin P, Seiwell R,. Furosemide in patients with heart failure. Shift of the dose-response relationship. Clin Pharmacol Ther 1980; 28: 182-186. (Pubitemid 10024871)
16. Brater DC, Seiwell R, Anderson S, Burdette A, Dehmer GJ, Chennavasin P,. Absorption and disposition of furosemide in congestive heart failure. Kidney Int 1982; 22: 171-176. (Pubitemid 12061651)
17. Brater DC, Day B, Burdette A, Anderson S,. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26: 183-189. (Pubitemid 14017057)
18. Brater DC,. Resistance to loop diuretics: why it happens and what to do about it. Drugs 1985; 30: 427-443. (Pubitemid 15240939)
19. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC,. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57: 601-609.
20. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P,. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28: 376-382. (Pubitemid 26274331)
21. Gottlieb SS, Khatta M, Wentworth D, Roffman D, Fisher ML, Kramer WG,. The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. Am J Med 1998; 104: 533-538. (Pubitemid 28328765)
22. Villeneuve JP, Verbeeck RK, Wilkinson GR, Branch RA,. Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther 1986; 40: 14-20. (Pubitemid 16057976)
23. Fredrick MJ, Pound DC, Hall SD, Brater DC,. Furosemide absorption in patients with cirrhosis. Clin Pharmacol Ther 1991; 49: 241-247.
24. Andreasen F, Hansen U, Husted SE, Jansen JA,. The pharmacokinetics of frusemide are influenced by age. Br J Clin Pharmacol 1983; 16: 391-397. (Pubitemid 13015763)
25. Branch RA, Roberts CJ, Homeida M, Levine D,. Determinants of response to frusemide in normal subjects. Br J Clin Pharmacol 1977; 4: 121-127. (Pubitemid 8068426)
26. Chennavasin P, Seiwell R, Brater DC, Liang WMM,. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 1979; 16: 187-195. (Pubitemid 10223979)
27. Smith DE, Lin ET, Benet LZ,. Absorption and disposition of furosemide in healthy volunteers measured with a metabolite-specific assay. Drug Metab Dispos 1980; 8: 337-342. (Pubitemid 10007718)
28. Uchino K, Isozaki S, Amano J, et al,. Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients. J Pharmacobiodyn 1983; 6: 684-691. (Pubitemid 14237915)
29. Meyer BH, Müller FO, Swart KJ, Luus HG, Werkman IM,. Comparative bio-Availability of four formulations of furosemide. S Afr Med J 1985; 68: 645-647. (Pubitemid 16195909)
30. Zhu J, Koizumi T,. A study on furosemide disposition in man. J Pharmacobiodyn 1987; 10: 370-376. (Pubitemid 18076060)
31. Alván G, Helleday L, Lindholm A, Sanz E, Villén T,. Diuretic effect and diuretic efficiency after intravenous dosage of frusemide. Br J Clin Pharmacol 1990; 29: 215-219. (Pubitemid 20131420)
32. Sommers DK, Meyer EC, Moncrieff J,. The influence of co-Administered organic acids on the kinetics and dynamics of frusemide. Br J Clin Pharmacol 1991; 32: 489-493.
33. Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP,. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol 1995; 39: 692-695.
34. McCrindle JL, Li Kam Wa TC, Barron W, Prescott LF,. Effect of food on the absorption of frusemide and bumetanide in man. Br J Clin Pharmacol 1996; 42: 743-746. (Pubitemid 26417616)
35. Wakelkamp M, Alván G, Gabrielsson J, Paintaud G,. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 1996; 60: 75-88. (Pubitemid 26279224)
36. Wakelkamp M, Alván G, Paintaud G,. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide. Br J Clin Pharmacol 1998; 45: 63-70. (Pubitemid 28062856)
37. Wakelkamp M, Alván G, Scheinin H, Gabrielsson J,. The influence of drug input rate on the development of tolerance to frusemide. Br J Clin Pharmacol 1998; 46: 479-487. (Pubitemid 28484736)
38. Wakelkamp M, Blechert A, Eriksson M, Gjellan K, Graffner C,. The influence of frusemide formulation on diuretic effect and efficiency. Br J Clin Pharmacol 1999; 48: 361-366. (Pubitemid 29417719)
39. Klausner EA, Lavy E, Stepensky D, et al,. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. J Clin Pharmacol 2003; 43: 711-720. (Pubitemid 36759148)
40. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krähenbühl S,. Sublingual administration of furosemide: new application of an old drug. Br J Clin Pharmacol 2007; 64: 804-809. (Pubitemid 350222067)
41. Vaidyanathan S, Bartlett M, Dieterich HA, et al,. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. Cardiovasc Ther 2008; 26: 238-246. doi: 10.1111/j.1755-5922.2008.00058.x.
42. Gehr TW, Sica DA, Brater C, Davis J, Fakhry I,. Furosemide pharmacokinetics and pharmacodynamics in renal transplantation. Clin Pharmacol Ther 1988; 43: 547-553.
43. Voelker JR, Cartwright-Brown D, Anderson S, et al,. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987; 32: 572-578. (Pubitemid 17154747)
44. Savic RM, Jonker DM, Kerbusch T, Karlsson MO,. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-726. (Pubitemid 47477040)
45. Piotrovskii VK,. The use of Weibull distribution to describe the in vivo absorption kinetics. J Pharm Biopharm 1987; 15: 681-686.
46. Petricoul O, Cosson V, Fuseau E, Marchand M,. Population models for drug absorption and enterohepatic recycling. In Pharmacometrics: The Science of Quantitative Pharmacology, Ette EI, Williams PJ, (eds). John Wiley & Sons: Hoboken (NJ), 2007: 345-382.
47. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
48. Beal SL,. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504. (Pubitemid 33151426)
49. Ahn JE, Karlsson MO, Dunne A, Ludden TM,. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008; 35: 401-421. doi: 10.1007/s10928-008-9094-4.
50. Bergstrand M, Karlsson MO,. Handling data below the limit of quantification in mixed effect models. AAPS J 2009; 11: 371-380. doi: 10.1208/s12248-009-9112-5.
51. Ahn JE, French JL,. Longitudinal aggregate data model-based meta-Analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 2010; 37: 179-201.
52. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13 (2): 143-151. doi: 10.1208/s12248-011-9255-z.
53. Williams PJ, Kim YH,. Resampling techniques and their application to pharmacometrics. In Pharmacometrics: The Science of Quantitative Pharmacology, Ette EI, Williams PJ, (eds). John Wiley & Sons: Hoboken (NJ), 2007.
54. Efron B, Gong G,. A leisurely look at the bootstrap, the jackknife, and cross validation. Am Statistician 1983; 37: 36-48.
55. Lindbom L, Pihlgren P, Jonsson EN,. PsN-Toolkit-A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-257. (Pubitemid 41196689)
56. Sutton AJ, Kendrick D, Coupland CAC,. Meta-Analysis of individual and aggregate-level data. Stat Med 2008; 27: 651-669.
57. Laporte-Simitsidis S, Girard P, Mismetti P, Chabaud S, Decousus H, Boissel JP,. Inter-study variability in population pharmacokinetic meta-Analysis: when and how to estimate it? J Pharm Sci 2000; 89: 155-167. (Pubitemid 30120796)
58. Ishak KJ, Platt RW, Joseph L, Hanley JA, Caro JJ,. Meta-Analysis of longitudinal studies. Clin Trials 2007; 4: 525-539. (Pubitemid 350189876)
59. Peters JL, Mengersen KL,. Meta-Analysis of repeated measures study designs. J Eval Clin Pract 2008; 14: 941-950.
60. Jones AP, Riley RD, Williamson PR, Whitehead A,. Meta-Analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials 2009; 6: 16-27.
61. Greenland S,. Divergent biases in ecologic and individual-level studies. Stat Med 1992; 11: 1209-1223.
62. Greenland S, Morgenstern H,. Ecological bias, confounding, and effect modification. Int J Epidemiol 1989; 18: 269-274. (Pubitemid 19128666)
63. Blakely TA, Woodward AJ,. Ecological effects in multi-level studies. J Epidemiol Community Health 2000; 54: 367-374 (Pubitemid 30204272)